Analysts anticipate Intra-Cellular Therapies to report an earnings per share (EPS) of $-0.19.
The market awaits Intra-Cellular Therapies's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Performance in Previous Earnings
During the last quarter, the company reported an EPS beat by $0.03, leading to a 1.07% increase in the share price on the subsequent day.
Here's a look at Intra-Cellular Therapies's past performance and the resulting price change:
Quarter
Q2 2024
Q1 2024
Q4 2023
Q3 2023
EPS Estimate
-0.19
-0.33
-0.43
-0.56
EPS Actual
-0.16
-0.16
-0.30
-0.25
Price Change %
1.0%
-6.0%
-2.0%
5.0%
Intra-Cellular Therapies Share Price Analysis
Shares of Intra-Cellular Therapies were trading at $76.82 as of October 28. Over the last 52-week period, shares are up 52.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analysts' Take on Intra-Cellular Therapies
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Intra-Cellular Therapies.
A total of 12 analyst ratings have been received for Intra-Cellular Therapies, with the consensus rating being Outperform. The average one-year price target stands at $102.08, suggesting a potential 32.88% upside.
Peer Ratings ...
